DoD Neurofibromatosis Investigator-Initiated Research Award

The summary for the DoD Neurofibromatosis Investigator-Initiated Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Neurofibromatosis Investigator-Initiated Research Award: The NFRP Investigator-Initiated Research Award (IIRA) mechanism was created in FY96. Since then, 263 Investigator-Initiated Research Award proposals have been received, and 82 have been recommended for funding.The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will (1) provide insight into the development of NF and related diseases, (2) result in substantial improvements over todays approach to the diagnosis and treatment of neurofibromatosis and/or Schwannomatosis, and (3) enhance the quality of life of persons with those diseases. Proposals must include preliminary data relevant to NF and the proposed project. In addition, if appropriate, a clear statistical plan of analysis should be included. Clinical trials are not acceptable under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas:. Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis;. Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities;. Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;. Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.Optional Collaborator: The FY08 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and industry scientists. Collaborations that bring new perspectives from other disciplines or bring new investigators into the NF field are also strongly encouraged. These types of collaborations will qualify for a higher level of funding as described in Section II.D. For the proposal to qualify for the higher level of funding, the PI must submit a PI Statement of Collaboration in addition to the letter of collaboration from the collaborator. The PI Statement of Collaboration must clearly identify the collaborating PI and address the following requirements:. The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement.. If the PI of the proposal does not have NF research experience, the collaborator must have experience in NF research as demonstrated through publications and/or funding history.. The collaborator must be at or above the level of Assistant Professor (or equivalent).. At least a 10% level of effort is required of the collaborator. Contribution of the collaborator should be reflected in the proposals budget.